FDA Inspection 886613 — Cipla Limited

Cipla Limited — FEI 3007021905

The FDA completed an inspection of Cipla Limited on June 25, 2014 in Mumbai. The inspection was classified OAI (Official Action Indicated — objectionable conditions were found and regulatory action is recommended). 6 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Official Action Indicated (OAI) (OAI)
End Date
June 25, 2014
Fiscal Year
2014
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Mumbai (India)

Additional Details

Postmarket Adverse Drug Experience (PADE)

Citations

IDCFRDescription
673021 CFR 314.80(b)Failure to develop written procedures
673221 CFR 314.80(c)(1)(i)Late submission of 15-day report
682321 CFR 314.80(c)Failure by applicant to report ADE
683221 CFR 314.80(c)(2)Late submission of annual safety reports
684221 CFR 314.80(j)Failure to maintain records
891221 CFR 314.81(b)(2)Timely submission